Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) 

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/human MHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma^[1][2][3].

Mouse IgG2a kappa

Mouse IgG2a kappa, Isotype Control

Human/Monkey

MHC class II

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (3 h) 可显著诱导 Raji、Ramos 和 Namalwa 细胞发生细胞裂解^[1]。
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (1-100 nM, 48-72 h) 可抑制 Raji 和 Daudi 细胞系的增殖^[1]。
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (4-24 h) 可诱导 Daudi 淋巴瘤细胞凋亡^[1]。
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (48 h) 可诱导一系列淋巴瘤细胞系中 caspase-3 和 AKT 的激活^[1]。
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (5 µg/mL, 3 h) 可诱导人内皮细胞发生坏死性细胞死亡，这个过程涉及细胞骨架重排^[2]。
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (5 µg/mL, 1 h) 可增加人内皮细胞中的细胞活性氧 (ROS) 并导致线粒体膜电位丧失^[2]。
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (5 µg/mL, 3 h) 可诱导内皮细胞溶酶体激活、溶酶体膜通透性改变及破裂^[2]。
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (3-6 days) 可选择性抑制已建立的 EB 病毒转化的淋巴母细胞系及 EB 病毒感染的 B 细胞的增殖^[3]。
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (5 µg/mL, 1 h) 下调淋巴母细胞系中 CD23 和 CD20 抗原的表达^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) (10-300 μg，腹腔注射，每周两次，持续 4 周) 可延长 Raji 肿瘤模型中小鼠模型的存活时间^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

3122  [NCBI]

P01903

ELISA, FACS, Functional assay, Research in vivo

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

液体

Colorless to light yellow

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Goulet DR, Atkins WM. Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci. 2020 Jan;109(1):74-103.  [Content Brief]

  [2]. Stein R, et al. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood. 2006 Oct 15;108(8):2736-44.  [Content Brief]

  [3]. Aljabri A, et al. HLA class II antibodies induce necrotic cell death in human endothelial cells via a lysosomal membrane permeabilization-mediated pathway. Cell Death Dis. 2019 Mar 8;10(3):235.  [Content Brief]

  [4]. Kabelitz D, et al. Growth inhibition of Epstein-Barr virus-transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down-regulation of CD23 antigen expression. Cell Immunol. 1989 Apr 15;120(1):21-30.  [Content Brief]